PL3100

PLx Pharma · Phase 2 active Small molecule

At a glance

Generic name	PL3100
Sponsor	PLx Pharma
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Clinical Trial Evaluating Gastrointestinal Damage Following Administration PL3100 or Naproxen in At-Risk Adults (PHASE2)
Oral Bioequivalence Study of PL 3100 and Naproxen in Healthy Adults (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PL3100 CI brief — competitive landscape report
PL3100 updates RSS · CI watch RSS
PLx Pharma portfolio CI